false-positives and unnecessary invasive procedures. 6 – 8 For example, PET/CT has been shown to be less sensitive for the detection of axillary lymph node metastases than axillary lymph node dissection or even physical examination. 9 Finally, advanced
Search Results
Arif Kamal, Tian Zhang, Steve Power, and P. Kelly Marcom
Neal Andruska, Benjamin W. Fischer-Valuck, Ruben Carmona, Temitope Agabalogun, Randall J. Brenneman, Hiram A. Gay, Jeff M. Michalski, and Brian C. Baumann
cancer, including radical prostatectomy with or without pelvic lymph node dissection, external-beam radiation therapy (EBRT) with 4 to 6 months of androgen deprivation therapy (ADT), or combination EBRT with a brachytherapy (BT) boost with or without ADT
Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell
with retroperitoneal lymph node dissection only? Which patients with stage II and III disease will need to undergo resection of residual masses after chemotherapy?” he continued. Dr. Gilligan explained that the 8th edition has made some changes, but
Presenters: Meena S. Moran and A. Marilyn Leitch
avoidance of axillary lymph node dissection (ALND) in many patients. This recommendation is largely based on findings from ACOSOG Z0011 and SINODAR-ONE, in which patients with clinical T1/T2N0 disease with up to 2 positive sentinel nodes fared equally well
Daniel G. Coit, John A. Thompson, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Adil Daud, Dominick DiMaio, Martin D. Fleming, Rene Gonzalez, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr, Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Mary C. Martini, Anthony J. Olszanski, Merrick I. Ross, April Salama, Susan M. Swetter, Kenneth K. Tanabe, Vijay Trisal, Marshall M. Urist, Nicole R. McMillian, and Maria Ho
as an isolated site of relapse underwent therapeutic lymph node dissection followed by either adjuvant radiation to the nodal basin or observation. 5 Eligible patients were required to have a lactate dehydrogenase (LDH) level less than 1.5 times the
Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse
omental caking. CA-125 serum tumor marker at time of presentation was elevated at 1,155 kU/L (normal range, <35 kU/L). The patient underwent primary surgery with radical hysterectomy, bilateral salpingo-oophorectomy, lymph node dissection, and removal of
James Mohler, Robert R. Bahnson, Barry Boston, J. Erik Busby, Anthony D'Amico, James A. Eastham, Charles A. Enke, Daniel George, Eric Mark Horwitz, Robert P. Huben, Philip Kantoff, Mark Kawachi, Michael Kuettel, Paul H. Lange, Gary MacVicar, Elizabeth R. Plimack, Julio M. Pow-Sang, Mack Roach III, Eric Rohren, Bruce J. Roth, Dennis C. Shrieve, Matthew R. Smith, Sandy Srinivas, Przemyslaw Twardowski, and Patrick C. Walsh
decision-making for men contemplating active surveillance, 12 radical prostatectomy, 13 – 15 neurovascular bundle preservation, 16 – 18 or omission of pelvic lymph node dissection (PLND) during radical prostatectomy, 19 brachytherapy, 13 , 20 , 21 or
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff, and Richard Zellars
pregnant during breast cancer treatment (see page 160). Locoregional Treatment Several randomized trials document that mastectomy with axillary lymph node dissection is equivalent to breast-conserving therapy with lumpectomy, axillary dissection
Andrea Maurichi, Rosalba Miceli, Roberto Patuzzo, Francesco Barretta, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Umberto Cortinovis, Elena Tolomio, Milena Sant, Gianpiero Castelli, Leonardo Zichichi, Giovanni Pellacani, Ignazio Stanganelli, Marco Simonacci, Ausilia Manganoni, Corrado Del Forno, Gioachino Caresana, Catherine Harwood, Daniele Bergamaschi, Konstantinos Lasithiotakis, Dorothy Bennett, Vittoria Espeli, Cristina Mangas, Sandra Leoni Parvex, Barbara Valeri, Mara Cossa, Marta Barisella, Alessandro Pellegrinelli, Claudia Miranda, Andrea Anichini, Roberta Mortarini, Odysseas Zoras, and Mario Santinami
completion lymph node dissection (CLND) as additional therapy. Statistical Methods Clinicopathologic characteristics were recorded according to SNB (performed vs not performed) for the whole series of patients, according to SN status (positive vs negative) in
Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk
treatment protocol is surgical resection, typically with radical hysterectomy and pelvic lymph node dissection. Cure rates are good in this instance. However, more advanced disease is a greater challenge to treat effectively. The American Cancer Society
